Answers are grounded in this paper and cite their sources.
A systematic review compares busulfan plus low dose melphalan and high dose melphalan in multiple myeloma, suggesting individualized treatment options.
BUMEL conditioning offers improved disease control at the cost of increased toxicity, without a clear overall survival advantage. These findings support individualized conditioning selection, particularly in settings where upfront ASCT remains standard practice.This protocol was registered on PROSPERO with an ID of CRD420261292372.
No takes yet. Share an insight, caveat, or question.
Maqbool et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: